linjc16/ctgov huggingface dataset:
Analyses of Cerebrospinalfluid in Patients With Delirium

Study Overview
=================
Brief Summary
-----------------
The current project aims to measure biomarkers in the cerebrospinalfluid (CSF) and serum samples from patients with delirium. We hope to uncover new insights into the pathophysiology of delirium and explore its link to dementia.

Detailed Description
-----------------
Delirium is a common and serious complication to acute illness, and is characterized by acute disturbances in attention, awareness, and cognition. Dementia is a major risk factor of delirium, and delirium increases the risk of dementia progression and development. As the conditions share both clinical and epidemiological features, some researchers suggest that also pathophysiological links are shared. Understanding delirium pathophysiology, which is poorly understood, may thus help elucidate early molecular mechanisms in dementia. This study aims to to increase our understanding of the pathophysiology of delirium and molecular links between delirium and dementia, by exploring cerebrospinal fluid (CSF) biomarkers.

Official Title
-----------------
MOLECULAR BIOMARKERS IN DELIRIUM AND DEMENTIA

Conditions
-----------------
Delirium

Intervention / Treatment
-----------------
* Procedure: Hip fracture surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with acute hip fracture Exclusion Criteria: Moribund patients. Lack of consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Hip fracture surgery|Hip fracture surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Delirium | Pre- and postoperative delirium | Daily during hospital stay (pre-/and postoperatively) until 5 days after surgery (or discharge) |
COVID 19 Viral Clearance Among the Infected Healthcare Workers In Assiut University Hospitals

Study Overview
=================
Brief Summary
-----------------
This work was aimed to determine the time of COVID 19 viral clearance in healthcare workers, assessment of clinical presentation and severity of COVID 19 infection among healthcare workers and discover relation between the time of COVID 19 viral clearance resolution of symptoms

Detailed Description
-----------------
COVID-19 has been spreading rapidly globally, with a considerable impact on global morbidity, mortality and healthcare utilization. This viral disease is caused by the Coronaviruses (CoV) which belong to the genus'coronavirus' of the Coronaviridae family. Coronaviruses are enveloped positive strand RNA viruses with the largest known RNA genomes-30-32 kb-with a 50 -cap structure and 30 -poly-A tail (Lei et al.2018). The transcription works through the replication-transcription complex (RCT) organized in double-membrane vesicles and via the synthesis of subgenomic RNAs (sgRNAs) sequences. Of note, transcription termination occurs at transcription regulatory sequences, located between the so-called open reading frames (ORFs). In the atypical CoV genome, at least six ORF scan could be present (Woo et al., 2020) . Health workers are at the front line of the COVID-19 outbreak response and as such are exposed to hazards that put them at risk of infection (Li e al.,2020). thus keeping the implementation of infection prevention and control (IPC) and its knowledge and practice are of great importance in healthcare settings to protect them from infections (Wang et al., 2020).

Official Title
-----------------
COVID19 Viral Clearance Among the Infected Healthcare Workers In Assiut University Hospitals

Conditions
-----------------
Infection, Coronavirus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Covid 19 infected healthcare workers. Exclusion Criteria: Risky healthcare workers (diabetic hypertensive and more than 50 years)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the time of Covid 19 viral clearance in medical healthcare workers and its relation to clinical presentation, severity among and resolution of symptoms. | different relations between different symptoms, investigation results and time of viral clearness | basline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| knowledge and practice of infection control measures | good and bad knowledge or practice | baseline |
Vascular Function, Insulin Sensitivity, and Vitamin D

Study Overview
=================
Brief Summary
-----------------
The overall objectives of this study are to examine the relationships between circulating vitamin D, insulin sensitivity, and multiple indices of vascular function and to examine whether vitamin D deficiency in African Americans (AA) and White Hispanics (WH) is responsible for ethnic differences in insulin sensitivity and hypertension in AA, WH and European Americans (EA), as well as mechanisms underlying the association between insulin resistance and blood pressure. We hypothesize that 1) serum 25(OH)D is associated with insulin sensitivity and vascular functioning, independent of adiposity, 2) lower insulin sensitivity and vascular functioning in AA and WH relative to EA is due to lower circulating 25(OH)D in AA, and 3) the relationship between insulin resistance and vascular dysfunction is mediated by 25(OH)D. Acronyms: African American (AA), European American (EA), White Hispanics (WH), Serum 25-hydroxy vitamin D (25()H)D, Body mass index (BMI), Alabama (AL).

Official Title
-----------------
Vitamin D, Vascular Function, and Insulin Sensitivity in Adults [The VIVID Study

Conditions
-----------------
Insulin Sensitivity, Flow-mediated Dilation, Arterial Stiffness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: African American (AA), White Hispanic (WH), and European American (EA) race Ages 19-60 years Negative urine pregnancy test No evidence of diabetes Not on medications that can affect vascular functioning or insulin sensitivity Exclusion Criteria: BMI > 32 kg/m2 Diabetes or any chronic diseases Use of medication(s) known to influence body composition, vascular function, or glucose metabolism Regular smoking Regular use of illegal drugs and pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy adults<br>healthy adults with BMI below 32, between ages 19-60 yrs, both males and females | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin sensitivity |  | Cross sectional study: at first study visit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vascular function |  | Cross sectional study: at second study visit, within 2 weeks of first study visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Insulin sensitivity, Vascular function, Flow-mediated dilation, Arterial stiffness, Glucose tolerance, Hypertension
Detection of GABHS in Throat Gargle

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to investigate the use of patient throat gargle as an alternative to throat swabbing for the diagnosis of pharyngitis caused by Group A β-Hemolytic Streptococcus (GABHS) infection, also known as strep throat.

Detailed Description
-----------------
The aim of this study is to procure a detailed quantitative and qualitative analysis of GABHS present in patient throat gargle and to compare various culturing techniques and immunoassay methods for efficient and effective GABHS detection from gargle fluid. During the course of this clinical trial, the following specimen samples will be collected from each participating patient: the patient will first be asked to gargle 10-15 mL of sterile saline to obtain a gargle sample, and then the patient will be subjected to two routine standard throat swabs. These specimen samples will be properly discarded after processing and analysis.

Official Title
-----------------
A Quantitative and Comparative Study for the Detection of Group A β-Hemolytic Streptococci in Patient Throat Gargle

Conditions
-----------------
Group A Streptococcus: B Hemolytic Pharyngitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older. Suspected of suffering from GABHS pharyngitis. Able to communicate with study personnel (English or Hebrew). Able to understand oral and written information about the study. Willing to provide written informed consent to participate in the study. Exclusion Criteria: Not capable of gargling 10-15 mL fluid. Diagnosed or self-reported pregnancy. History of dementia, cognitive impairment, or psychiatric or mental disorders.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparative: Method sensitivity to investigate method effectiveness. | Compare sensitivity of each gargle fluid GABHS detection method. | Through study completion, about 9 months | 
| Comparative: Method specificity to investigate method effectiveness. | Compare specificity of each gargle fluid GABHS detection method. | Through study completion, about 9 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantitative: Average GABHS in gargle. | Average number of total GABHS bacteria collected in throat gargle samples. | Through study completion, about 9 months | 
| Quantitative: Minimum GABHS in gargle. | Minimum number of total GABHS bacteria collected in throat gargle samples. | Through study completion, about 9 months |
Tissue Engineering Microtia Auricular Reconstruction: in Vitro and in Vivo Studies

Study Overview
=================
Brief Summary
-----------------
Platelet-rich plasma (PRP) has mixed growth factors such as TGF-ß1 and TGF-ß2, vascular epithelial growth factor (VEGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF). These growth factors appear to play an important role in wound healing and are assumed as promoters of tissue regeneration. Moreover, PRP was used as injectable scaffold seeded with chondrocytes to regenerate cartilage. In their previous study, the investigators concluded that growth factors in PRP can effectively react as a growth factor cocktail to induce human nucleus pulposus proliferation and differentiation, and also promote tissue-engineered nucleus pulposus formation. The investigators also have a hypothesis that PRP can promote tissue-engineered microtia auricular cartilage formation. TGF- ß1 exists in the highest concentration and is more important among all of the growth factors released from PRP. So TGF- ß1 can be used as the core ingredient and the indicator for applying PRP in these studies. The aim of this study was to compare the histological and biochemical character of microtia chondrocytes treated with and without PRP.

Official Title
-----------------
Tissue Engineering Microtia Auricular Reconstruction: in Vitro and in Vivo Studies

Conditions
-----------------
Microtia

Intervention / Treatment
-----------------
* Other: Platelet-rich plasma (PRP)
* Other: Chondrocyte culture with FBS medium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: microtia patient Exclusion Criteria: non microtia patient
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Arm A<br>Chondrocyte culture with FBS medium | Other: Chondrocyte culture with FBS medium<br>* Microtia chondrocyte culture with FBS medium only<br>|
| Experimental: Arm B<br>Chondrocyte culture with PRP | Other: Platelet-rich plasma (PRP)<br>* PRP was extracted from total blood and TGF-b1 was used as indicator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The aim of this study was to compare the histological and biochemical character of microtia chondrocytes treated with and without PRP. |  | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tissue engineering
ATAC - Endometrial Sub-Protocol

Study Overview
=================
Brief Summary
-----------------
To compare the difference between the ARIMIDEX group and the tamoxifen group in the incidence of abnormal endometrial histological findings arising after treatment has commenced.

Official Title
-----------------
A Randomised, Double Blind Trial to Assess the Incidence of Endometrial Changes With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: Anastrozole (Arimidex)
* Drug: Tamoxifen (Nolvadex)
* Drug: Nolvadex placebo
* Drug: Arimidex placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients eligible for entry into the main ATAC trial (1033IL/0029) Not received any previous tamoxifen, for whatever reason Not undergone a hysterectomy and do not have a hysterectomy planned within the next 6 years No previous endometrial ablation Exclusion Criteria: Excluded from entry into the main ATAC trial (1033IL/0029). As detailed in Section 4.4 of the main ATAC trial (1033IL/0029)

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Arimidex 1mg + Nolvadex placebo | Drug: Anastrozole (Arimidex)<br>* 1mg, orally, once daily<br>* Other names: Arimidex;Drug: Nolvadex placebo<br> <br> |
| Active Comparator: 2<br>Arimidex placebo + Nolvadex 20mg | Drug: Tamoxifen (Nolvadex)<br>* 20mg, orally, once daily<br>* Other names: Nolvadex;Drug: Arimidex placebo<br> <br> |
| Active Comparator: 3<br>Arimidex 1mg + Nolvadex 20mg | Drug: Anastrozole (Arimidex)<br>* 1mg, orally, once daily<br>* Other names: Arimidex;Drug: Tamoxifen (Nolvadex)<br>* 20mg, orally, once daily<br>* Other names: Nolvadex;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Withdrawl |  |  | 
| Death |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endometrial, Endometrial histological findings
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma

Study Overview
=================
Brief Summary
-----------------
AMP-activated protein kinase (AMPK) is an evolutionally conserved protein kinase that serves as an energy guardian to help cells adapt to various metabolic stress including hypoxia. Because the role of AMPK in cancers has not been fully elucidated, in this study we investigated the expression and activation of AMPK in lung adenocarcinoma (LADC) cells and tissue.

Official Title
-----------------
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma

Conditions
-----------------
Lung Adenocarcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lung cancer received operation lobectomy in CMUH Exclusion Criteria: History of uremia, other malignant disease, and liver cirrhosis History of pneumonia and pulmonary tuberculosis History of long period of medications.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMP-activated protein kinase, lung adenocarcinomas, Prognosis, Observation study
Serial Measurement of a Plasma Stroke Biomarker Panel in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate changes in new plasma stroke biomarker panel in patients undergoing cardiac surgery with the use of cardiopulmonary bypass.

Official Title
-----------------
Serial Measurement of a Plasma Stroke Biomarker Panel in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

Conditions
-----------------
Cardiac Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Elective cardiac surgery with the use of cardiopulmonary bypass Exclusion Criteria: Patients undergoing emergent procedures Patients with preoperative mechanical support

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stroke Panel group<br>Patients undergoing cardiac surgery with the use of cardiopulmonary bypass | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in stroke index |  | day before surgery; first and second day postoperatively |
Cerebral Microembolism During Hemodialysis

Study Overview
=================
Brief Summary
-----------------
There is increasing evidence that renal replacement therapy (= continuous veno-venous hemodialysis) generates cerebral microembolism which is detectable on transcranial Doppler ultrasound. The aim of this study is to monitor patients with transcranial Doppler under two conditions: during hemodialysis and in a hemodialysis-free interval (in each period cerebral embolic load is detected during 30 minutes). The study hypothesis is that during hemodialysis the cerebral embolic load is significantly higher than in the hemodialysis-free interval.

Official Title
-----------------
Quantity, Quality and Laterality of Cerebral Microembolism During Veno-Venous Hemodialysis.

Conditions
-----------------
Complication of Dialysis, Thrombus Due to Renal Dialysis Device, Implant, or Graft, Cerebral Embolism

Intervention / Treatment
-----------------
* Device: Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Renal replacement therapy (continuous veno-venous hemodilalysis) on the in-house intensive care unit Age > 18yrs and < 90yrs Exclusion Criteria: Absent informed consent Preexistent neurological morbidity Neurocognitive disturbances Carotid artery stenosis > 70% Patent foramen ovale Treatment with other extracorporeal devices Cardial pathology (valvular heart disease, prosthesis, endocarditis) Pregnancy, drug abuse Inclusion in an other clinical study Allergy against materials of the medical device used in the study (transcranial Doppler) or temporal skin/bone lesions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient on Hemodialysis<br>Renal hemodialysis | Device: Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)<br>* Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.<br>* Other names: Continuous veno-venous hemodialysis;|
| Patient in a hemodialysis-free interval<br>No Renal hemodialysis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantity of cerebral embolic load | Cerebral embolic load is measured in a 30 minutes-interval during hemodialysis and in a hemodialysis-free interval. | 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality and laterality of cerebral embolic load | Quality (solid vs. gaseous) and laterality (left vs. right hemispheric dominance) of cerebral embolic load is measured in a 30 minutes-interval during hemodialysis and in a hemodialysis-free interval. | 30 minutes |